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Abstract
Objective: to evaluate primary care drug utilisation during the last year of life, focusing on antidiabetic and cardiovascular
drugs, in patients of advanced age with diabetes.
Design: population-based cohort study.
Setting: primary care database in the UK.
Subjects: patients with type 2 diabetes who died at over 80 years of age between 2011 and 13.
Methods: main outcome measures included proportions of patients prescribed different classes of drugs, comparing the
ﬁrst (Q1) and the fourth quarters (Q4) of the last year of life.
Results: the study included 5,324 patients, with the median age 86 years and 50% female. Three-fourths of the patients
received ﬁve or more drugs, and the total number of drugs prescribed was almost stable at 6.2 ± 3.1 (mean ± SD) during
the last year of life. Substantial proportions of patients were treated with antidiabetic drugs (78%), antihypertensive drugs
(76%), statins (62%) and low-dose aspirin (46%) in Q1. Prescribing of these drugs slightly decreased by 3–8% in Q4. There
were increases in prescribing of anti-infectives (35% in Q1 to 50% in Q4), drugs for nervous system (63% to 73%), drugs
for respiratory system (24% to 33%) and systemic hormonal drugs (22% to 27%).
Conclusion: patients of advanced age with type 2 diabetes were often treated with antidiabetic and cardiovascular drugs
even when approaching death. More research is needed to generate evidence to guide optimal drug utilisation for older peo-
ple with a limited life expectancy.
Keywords: aged, 80 and over, end-of-life care, older people, polypharmacy, type 2 diabetes mellitus
Introduction
The number of very old people is increasing, and both the
prevalence of chronic diseases, including diabetes, and the
intensity of drug treatment have been increasing in this
population [1]. Patients with diabetes are commonly trea-
ted with multiple classes of drugs to control risk factor
values and to reduce cardiovascular risk, consistent with
guideline recommendations [2]. These recommendations
are often applied in very old people over 80 years of
age [3]. Drugs to lower cardiovascular risk are often
prescribed for several decades or even life-long, despite
lack of evidence for such a long-term therapy [4]. Some
observational studies suggest that low levels of cardiovas-
cular risk factors, including HbA1c, blood pressure and
cholesterol, may sometimes be associated with higher mor-
tality in very old patients with type 2 diabetes [5]. As patients
approach the end-of-life, care to control symptoms and to
improve well-being become important. At present, there is
insufﬁcient evidence to guide end-of-life care for patients
with diabetes [6, 7]. This study aimed to evaluate primary
care drug utilisation during the last year of life, focusing on
antidiabetic and cardiovascular drugs, in patients of advanced
age with diabetes.
147
Methods
Patients
Patients 80 years or older with type 2 diabetes who died
between 2011 and 13 were sampled from the UK Clinical
Practice Research Datalink (CPRD). CPRD collects elec-
tronic health records from primary care across the UK, and
participants are representative of general population [8].
Patients with type 2 diabetes were selected based on diagno-
ses of diabetes, HbA1c values and prescriptions of antidia-
betic drugs. Patients who consulted their general
practitioners at least once every 3 months in the last year of
life were selected to include community-dwelling people
who were generally managed in primary care. Patients who
ended their registration with a CPRD general practice
before death were excluded. The study was approved by
the CPRD Independent Scientiﬁc Advisory Committee
(ISAC Protocol 14_053).
Measurements
All drugs prescribed, except for topical drugs for local
effects, vitamins/minerals, nutritional products, herbal rem-
edy or vaccines, were evaluated regardless of duration of
treatment. We focused on antidiabetic drugs and cardiovas-
cular drugs for prevention and treatment of cardiovascular
diseases (CVD), including antihypertensive drugs, statins
and low-dose aspirin. Numbers of drug classes for individ-
ual patients were evaluated according to the third level
(pharmacological subgroup; e.g. A10A insulins and analo-
gues) of the WHO ATC classiﬁcation.
Analysis
Baseline characteristics were evaluated at the start of obser-
vation (i.e. 365 days before death dates). Frequencies and
proportions of patients prescribed each class of drugs were
calculated in the ﬁrst (Q1; 12–9 months before death) and
the fourth quarters (Q4; 3 months before death to death
dates) of the last year of life. Analysis was performed in
overall and according to a history of CVD (coronary heart
disease and stroke). Changes in prescriptions from Q1 to
Q4 and differences in prescriptions between patients with
CVD and those without were tested. Total numbers of
drug classes were counted on the monthly basis.
Results
Characteristics of patients
The study included 5,324 patients, with the median age 86
years and 50% female (Table 1). The median duration of
diabetes was 10 years. Half of the patients had a history of
CVD. Two-thirds of the patients had estimated glomerular
ﬁltration rate (eGFR) of <60 mL/min/1.73 m2, calculated
using the Chronic Kidney Disease Epidemiology
Collaboration equation [9]. A majority of the patients were
managed their cardiovascular risk factors below relaxed tar-
gets for HbA1c (<8.5% or <69 mmol/mol), blood pressure
(systolic <150 and diastolic <90 mmHg) and total choles-
terol (<5.0 mmol/L).
Antidiabetic and cardiovascular drugs
Most of the patients (78%) were treated with antidiabetic
drugs during the last year of life (Table 2). Metformin and
sulphonylureas were prescribed frequently at similar levels
in overall. Metformin was less frequently prescribed in
patients with decreased renal function: among patients on
antidiabetic medications, although 70% of the patients with
eGFR ≥60 mL/min/1.73 m2 received metformin, 35% or
14% of the patients with eGFR <45 or <30 mL/min/
1.73 m2, respectively, received this drug. Insulins were more
frequently prescribed in patients with a history of CVD
compared with those without (P < 0.001). A slight decrease
(6%) in prescribing of antidiabetic drugs were observed
from Q1 to Q4 (P < 0.001). Substantial proportions of
patients were treated with antihypertensive drugs (76%),
statins (62%) and low-dose aspirin (46%) in Q1. Patients
with a history of CVD had more intensive pharmacological
treatment with the cardiovascular drugs than those without
(all P < 0.001). Prescribing of the cardiovascular drugs
decreased by 3–8% from Q1 to Q4 as patients approached
death (all P < 0.001).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Characteristics of patients (N = 5,324)
Characteristics n (%)/
Median (IQR)
Sex Male 2,656 (50)
Female 2,668 (50)
Age (years) 86 (83–89)
Duration of diabetes (years) 10 (6–16)
eGFR (mL/min/1.73 m2) <30 773 (15)
30–44 1,290 (24)
45–59 1,306 (25)
≥60 1,955 (37)
HbA1c (%, mmol/mol) <6.5 (<48) 1,164 (22)
6.5–7.4 (48–57) 1,901 (36)
7.5–8.4 (58–68) 876 (16)
≥8.5 (≥69) 1,383 (26)
Systolic/diastolic blood
pressure (mmHg)a
<130 and <70 1,156 (23)
<140 and <80 (but ≥130 or ≥70) 1,770 (36)
<150 and <90 (but ≥140 or ≥80) 1,236 (25)
≥150/90 817 (16)
Total cholesterol (mmol/L) <3.0 531 (10)
3.0–3.9 1,721 (32)
4.0–4.9 1,431 (27)
≥5.0 1,641 (31)
Comorbidities Cardiovascular disease 2,710 (51)
Coronary heart disease 2,260 (42)
Stroke 815 (15)
Cancer 1,875 (35)
Dementia/Cognitive decline 673 (13)
eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range.
aExcluding 345 patients with missing values for blood pressure.
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Overall prescriptions
Drugs in ATC main groups B (e.g. low-dose aspirin and
warfarin) and C (e.g. antihypertensive drugs, statins, diure-
tics and drugs for angina) were less prescribed in Q4
compared with Q1 (B, 66% in Q1 to 61% in Q4; C, 90%
to 84%). Drugs in group J (anti-infectives for systemic use)
were increased most (35% in Q1 to 50% in Q4), followed
by group N (nervous system, 63% to 73%), group R (respira-
tory system, 24% to 33%) and group H (systemic hormonal
preparations; e.g. thyroid hormones and corticosteroids, 22%
to 27%). Other frequently prescribed groups of drugs (group
A, 91% to 90%; G, 15% to 16% and M, 22% to 21%) were
prescribed at similar levels between Q1 and Q4.
In patients who received any of the drugs of interest in
a given month (79–92% of the overall patients), the total
number of drugs prescribed was almost stable at 6.2 ± 3.1
(mean ± SD) during the last year of life, and 55% or 18%
of the patients received 5–9 or 10 different classes of drugs
in a month.
Discussion
This study showed that very old people with diabetes
received intense pharmacological treatment with antidiabetic
and cardiovascular drugs during the last year of life. We
caution that the study cohort were selected because they
died, but death may not always have been clearly antici-
pated. Their care may not have been recognised as being
for the end-of-life. Prescribing might be justiﬁed if patients
were expected to live longer than the time needed to obtain
beneﬁts from the drugs. Even if antidiabetic medications
do not exert preventive effects on long-term complications
due to a short period of follow-up, blood glucose lowering
may reduce risks for infections and dehydration at the end-
of-life phase. However, avoidance of diabetes-related emer-
gent complications, such as hypoglycaemia, is an important
aspect of care for older patients with diabetes [7]. Potential
overtreatment of blood glucose and blood pressure in older
people were recently reported in the USA [10, 11].
However, clinicians may be reluctant to de-escalate treat-
ment in patients with evidence of complications. These
ﬁndings may be partly supported by the perception of a dif-
ﬁculty in making decisions on deintensiﬁcation of drug
treatment for future risk reduction [12]. Polypharmacy was
commonly observed in this study, which could be a great
concern because of increased risks of drug–drug interac-
tions and adverse events [13, 14]. Further research on
reducing inappropriate drugs in patients approaching the
end-of-life is needed [15].
‘Deprescribing’ is a medication review process of dis-
continuing drugs to improve outcomes and decrease risks
associated with polypharmacy [16]. So far, some recom-
mendations on end-of-life care in patients with diabetes
have been provided based on available clinical evidence
[6, 7, 17]. Evidence supporting decision-making of discon-
tinuation of drugs may be generated from clinical studies or
observational studies with careful consideration of con-
founding by indication. A recent randomised controlled trial
suggested that discontinuation of statins appeared to be
safe, might improve quality of life and reduced medication
costs in patients with a limited life expectancy [18].
However, some issues were indicated in the study [19, 20],
which can be also challenges for deprescribing trials in the
future. Further research is required on how to generate and
utilise evidence to reduce the inappropriate use of drugs in
such populations.
There were some limitations in this study although the
CPRD provided a representative sample of the UK general
population. First, we did not separate patients based on an
estimated life expectancy or analyse causes of deaths, which
made it difﬁcult to evaluate appropriateness of prescribing.
Second, we could not know if patients actually took their
medications prescribed from the database. Some patients
might have discontinued taking the drugs prescribed, espe-
cially in the last few months of life. Third, we analysed data
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Prescriptions of antidiabetic and cardiovascular drugs in the last year of life
Overall (N = 5,324) No history of CVD (N = 2,614) History of CVD (N = 2,710)
Q1 Q4 P value Q1 Q4 P value Q1 Q4 P value
Antidiabetic drugs 4,164 (78) 3,816 (72) <0.001 2,048 (78) 1,864 (71) <0.001 2,116 (78) 1,952 (72) <0.001
Insulins 791 (15) 768 (14) 0.189 321 (12) 310 (12) 0.351 470 (17) 458 (17) 0.355
Metformin 2,316 (44) 2,054 (39) <0.001 1,186 (45) 1,046 (40) <0.001 1,130 (42) 1,008 (37) <0.001
Sulphonylureas 2,215 (42) 1,937 (36) <0.001 1,130 (43) 989 (38) <0.001 1,085 (40) 948 (35) <0.001
Other antidiabetic drugs 433 (8) 388 (7) 0.002 242 (9) 210 (8) 0.002 191 (7) 178 (7) 0.173
Antihypertensive drugs 4,053 (76) 3,629 (68) <0.001 1,882 (72) 1,647 (63) <0.001 2,171 (80) 1,982 (73) <0.001
RAS blockers 3,037 (57) 2,510 (47) <0.001 1,387 (53) 1,133 (43) <0.001 1,650 (61) 1,377 (51) <0.001
β-blockers 1,648 (31) 1,676 (31) 0.205 552 (21) 559 (21) 0.622 1,096 (40) 1,117 (41) 0.215
Ca-channel blockers 1,554 (29) 1,304 (24) <0.001 797 (30) 676 (26) <0.001 757 (28) 628 (23) <0.001
Thiazide diuretics 700 (13) 498 (9) <0.001 428 (16) 292 (11) <0.001 272 (10) 206 (8) <0.001
Statins 3,290 (62) 2,850 (54) <0.001 1,389 (53) 1,179 (45) <0.001 1,901 (70) 1,671 (62) <0.001
Low-dose aspirin 2,461 (46) 2,281 (43) <0.001 1,006 (39) 943 (36) 0.001 1,455 (54) 1,338 (49) <0.001
CVD, cardiovascular diseases. Data are shown as frequencies (%).
Q1, 12–9 months before death; Q4, 3 months before death to death dates.
RAS blockers: drugs affecting the renin–angiotensin system.
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from primary care, including some over-the-counter drugs
recorded in the CPRD but did not include drugs prescribed in
hospitals or care facilities. Finally, the study cohort managed in
primary care might have different health status and intensity
of pharmacological treatment compared with those managed
in other settings, which may limit generalisability of the results.
Conclusion
Patients with type 2 diabetes were often treated with anti-
diabetic and cardiovascular drugs even in their advanced
ages approaching death. Deprescribing might be considered
for this population when patients are not expected to have
enough time to obtain beneﬁts from the medications or
patients are at substantial risks of symptomatic adverse
events. More research is needed to generate evidence to
guide optimal drug utilisation for older people with a lim-
ited life expectancy.
Key points
• Prescribing of medications during the last year of life in
primary care was evaluated in older patients with diabetes.
• Patients with diabetes were often treated with antidiabetic
and cardiovascular drugs at the end-of-life.
• Discontinuation of some of drugs might be considered to
improve outcomes and decrease risks of adverse events.
• More research is needed to generate evidence to guide
optimal drug utilisation for this vulnerable population.
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Abstract
Background/Objective: although poorly documented, subcutaneous (SC) administration of antibiotics is common practice
in France especially in Geriatrics Departments. The aim of this study was to determine the tolerance of such a practice.
Design: prospective observational multicentre study.
Methods: sixty-six physicians accepted to participate from 50 French Infectious Diseases and Geriatrics Departments. From
May to September 2014, patients treated at least one day with SC antibiotics could be included. Modalities of subcutaneous admin-
istration, occurrence of local and systemic adverse effects (AE) and clinical course were collected until the end of the treatment.
Results: two hundred-nineteen patients (83.0 [19–104] yo) were included. Ceftriaxone (n = 163, 74.4%), and ertapenem (n = 30,
13.7%) were the most often prescribed antibiotics. The SC route was mainly used because of poor venous access (65.3%) and/or
palliative care (32.4%). Fifty patients (22.8%) experienced at least one local AE that led to an increased hospital stay for two patients
(4.0%) and a discontinuation of the SC infusion in six patients (12.0%). A binary logistic regression for multivariate analysis identiﬁed
the class of antibiotic (p = 0.002) especially teicoplanin and the use of rigid catheter (p = 0.009) as factors independently asso-
ciated with AE. In over 80% of cases, SC antibiotics were well tolerated and associated with clinical recovery.
Conclusions: SC administration of antibiotics leads to frequent but local and mild AE. Use of non-rigid catheter appears
to be protective against AE. As it appears to be a safe alternative to the intravenous route, more studies are needed regarding
efﬁcacy and pharmacokinetics.
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